Real-world comparative effectiveness of ARNI versus ACEi/ARB in HF with reduced or mildly reduced ejection fraction

AIMS: Sacubitril/valsartan is a first-in-class angiotensin receptor–neprilysin inhibitor (ARNI) with a class-1 guideline recommendation. We assessed the real-world effectiveness of ARNI versus angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB) on all-cause and cardiovasc...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Michael, Pivodic, Aldina, Käck, Oskar, Costa-Scharplatz, Madlaina, Dahlström, Ulf, Lund, Lars H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Original Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849288/
https://www.ncbi.nlm.nih.gov/pubmed/36443599
http://dx.doi.org/10.1007/s00392-022-02124-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9849288/
https://www.ncbi.nlm.nih.gov/pubmed/36443599
http://dx.doi.org/10.1007/s00392-022-02124-w

Ejemplares similares